NEW YORK (Reuters Health)—Medical cannabis reduces chronic pain patients’ opioid use, while improving their quality of life, according to a new survey of Michigan cannabis dispensary patrons. “They report that when they make that switch they overall feel better,” Dr. Daniel J. Clauw of the University of Michigan, Ann Arbor, told Reuters Health in a…
Abaloparatide Effective for Osteoporosis & XmAb5871 Studied to Treat SLE
Abaloparatide has completed clinical trials, which showed the treatment to be safe and effective in reducing fracture rates in postmenopausal women with osteoporosis. Also, XmAb5871 is being studied to treat systemic lupus erythematosus and doesn’t destroy B cells…
U.S. FDA Approves Lilly’s Ixekizumab for Plaque Psoriasis
(Reuters)—U.S. health regulators said on Tuesday they have approved a drug from Eli Lilly and Co. to treat adults with moderate to severe cases of plaque psoriasis. The injectable drug known chemically as ixekizumab will be sold under the brand name Taltz, the U.S. Food and Drug Administration said. Taltz works by blocking interleukein-17A, a…
From the Expert: Patient Access Is Key for Biosimilars in Development to Be Effective
Recent research by Michael Weinblatt, MD, and colleagues has demonstrated that a biosimilar derived from adalimumab is both effective and safe for treating patients with rheumatoid arthritis. But Dr. Weinblatt says, the benefits of such biosimilars hinge on cost and patient access…
Health Insurer Anthem Sues Express Scripts over Drug Pricing
(Reuters)—Health insurer Anthem Inc. said it had sued pharmacy benefit manager Express Scripts Holding Co. to recover damages from drug pricing it believes was too high. The lawsuit, filed on Monday in U.S. District Court for the Southern District of New York, is the latest development in a month’s long dispute over Anthem’s contract with…
Older Americans Taking More Medications
(Reuters Health)—The proportion of older Americans taking at least five medications or supplements went up in a recent study. The increase in people using multiple medications paralleled an increase in the number of older Americans at risk for major drug interactions, researchers found. “That’s a concern from a public health standpoint, because it’s getting worse,”…
FDA Says It Requires Boxed Warning on Some Opioid-Based Painkillers
(Reuters)—The U.S. Food and Drug Administration announced on Tuesday new required class-wide safety labeling changes for immediate-release opioid pain medications. Among the changes, the FDA now requires these pain medications to carry a new boxed warning about the serious risks of misuse, abuse, addiction, overdose and death. The FDA also requires several additional safety labeling…
Plaque Psoriasis: Secukinumab Beats Ustekinumab in a Head-to Head Clinical Trial & Ixekizumab Helps Improve Productivity
In a 52-week clinical trial, patients with plaque psoriasis who took secukinumab achieved greater sustained skin clearance then those taking ustekinumab. Also, three clinical trials showed ixekizumab improves work productivity in patients with plaque psoriasis…
U.S. Agency Issues New Guidelines to Limit Chronic Use of Opioids
(Reuters)—Addressing a growing “epidemic” of opioid overdoses and abuse of the prescribed painkillers in the U.S., the Centers for Disease Control and Prevention on Tuesday released voluntary guidelines that instruct primary care doctors to sharply deter use of the medicines for chronic pain. “Overprescribing opioids, largely for chronic pain, is a key driver of America’s…
Psoriasis Drug Succeeds in Mid-Stage Study
(Reuters)—Drug developer Vitae Pharmaceuticals Inc. said its experimental psoriasis drug significantly reduced the skin condition in patients from a mid-stage trial, sending its shares up 70% in after-hours trading. Patients taking a 350 mg dose of the drug, VTP-43742, showed a 24% reduction, while patients who took the 700 mg dose showed a 30% reduction…
- « Previous Page
- 1
- …
- 84
- 85
- 86
- 87
- 88
- …
- 120
- Next Page »